Validation of the Movement Disorder Society Criteria for the Diagnosis of 4‐Repeat Tauopathies

The Movement Disorder Society criteria for progressive supranuclear palsy introduced the category “probable 4‐repeat (4R)‐tauopathy” for joint clinical diagnosis of progressive supranuclear palsy and corticobasal degeneration.

[1]  W. Oertel,et al.  How to apply the movement disorder society criteria for diagnosis of progressive supranuclear palsy , 2019, Movement disorders : official journal of the Movement Disorder Society.

[2]  W. Meissner,et al.  Four-repeat tauopathies , 2019, Progress in Neurobiology.

[3]  Peter R. Martin,et al.  Sensitivity and Specificity of Diagnostic Criteria for Progressive Supranuclear Palsy , 2019, Movement disorders : official journal of the Movement Disorder Society.

[4]  J. Rowe,et al.  Neuropathological validation of the MDS-PSP criteria with PSP and other frontotemporal lobar degeneration , 2019, bioRxiv.

[5]  J. Passchier,et al.  Disease-related patterns of in vivo pathology in Corticobasal syndrome , 2018, European Journal of Nuclear Medicine and Molecular Imaging.

[6]  G. Höglinger.  Is it Useful to Classify Progressive Supranuclear Palsy and Corticobasal Degeneration as Different Disorders? No , 2018, Movement disorders clinical practice.

[7]  A. Lang,et al.  Advances in progressive supranuclear palsy: new diagnostic criteria, biomarkers, and therapeutic approaches , 2017, The Lancet Neurology.

[8]  Murray Grossman,et al.  Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria , 2017, Movement disorders : official journal of the Movement Disorder Society.

[9]  S. Lorenzl,et al.  Which ante mortem clinical features predict progressive supranuclear palsy pathology? , 2017, Movement disorders : official journal of the Movement Disorder Society.

[10]  Luca Passamonti,et al.  18F-AV-1451 positron emission tomography in Alzheimer’s disease and progressive supranuclear palsy , 2017, Brain : a journal of neurology.

[11]  K. Blennow,et al.  Detailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer disease , 2015, Neurology.

[12]  G. Kovacs,et al.  Invited review: Neuropathology of tauopathies: principles and practice , 2015, Neuropathology and applied neurobiology.

[13]  E. Tolosa,et al.  The phenotypic spectrum of progressive supranuclear palsy: A retrospective multicenter study of 100 definite cases , 2014, Movement disorders : official journal of the Movement Disorder Society.

[14]  Nick C Fox,et al.  Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria , 2014, The Lancet Neurology.

[15]  J. Hodges,et al.  Edinburgh Research Explorer Validation of the New Consensus Criteria for the Diagnosis of Corticobasal Degeneration , 2022 .

[16]  Mark Hallett,et al.  Criteria for the diagnosis of corticobasal degeneration , 2013, Neurology.

[17]  A. Lees,et al.  Does corticobasal degeneration exist? A clinicopathological re-evaluation. , 2010, Brain : a journal of neurology.

[18]  Thomas Gasser,et al.  Neuropathological assessment of Parkinson's disease: refining the diagnostic criteria , 2009, The Lancet Neurology.

[19]  John Q. Trojanowski,et al.  Nomenclature and nosology for neuropathologic subtypes of frontotemporal lobar degeneration: an update , 2009, Acta Neuropathologica.

[20]  J. Trojanowski,et al.  Proposed neuropathological criteria for the post mortem diagnosis of multiple system atrophy , 2007, Neuropathology and applied neurobiology.

[21]  P. Lantos,et al.  Office of Rare Diseases Neuropathologic Criteria for Corticobasal Degeneration , 2002, Journal of neuropathology and experimental neurology.

[22]  D. Dickson.  Neuropathologic differentiation of progressive supranuclear palsy and corticobasal degeneration , 1999, Journal of Neurology.

[23]  I Litvan,et al.  Preliminary NINDS neuropathologic criteria for Steele‐Richardson‐Olszewski syndrome (progressive supranuclear palsy) , 1994, Neurology.

[24]  Young T. Hong,et al.  18 FAV-1451 positron emission tomography in Alzheimer ’ s disease and progressive supranuclear palsy , 2017 .